AZN
Price
$66.63
Change
-$0.28 (-0.42%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
208.98B
20 days until earnings call
BIIB
Price
$140.58
Change
-$0.65 (-0.46%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
31.34B
13 days until earnings call
Ad is loading...

AZN vs BIIB

Header iconAZN vs BIIB Comparison
Open Charts AZN vs BIIBBanner chart's image
AstraZeneca
Price$66.63
Change-$0.28 (-0.42%)
Volume$82.73K
Capitalization208.98B
Biogen
Price$140.58
Change-$0.65 (-0.46%)
Volume$12.83K
Capitalization31.34B
AZN vs BIIB Comparison Chart
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. BIIB commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Hold and BIIB is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (AZN: $66.91 vs. BIIB: $141.23)
Brand notoriety: AZN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 69% vs. BIIB: 79%
Market capitalization -- AZN: $208.98B vs. BIIB: $31.34B
AZN [@Pharmaceuticals: Major] is valued at $208.98B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $31.34B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 1 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • AZN’s FA Score: 1 green, 4 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, AZN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 2 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s).

  • AZN’s TA Score: 2 bullish, 4 bearish.
  • BIIB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than AZN.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а +0.50% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -6.32% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.33%. For the same industry, the average monthly price growth was -0.62%, and the average quarterly price growth was -7.03%.

Reported Earning Dates

AZN is expected to report earnings on Apr 25, 2025.

BIIB is expected to report earnings on Apr 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZN($209B) has a higher market cap than BIIB($31.3B). AZN has higher P/E ratio than BIIB: AZN (35.30) vs BIIB (26.95). AZN YTD gains are higher at: 2.122 vs. BIIB (-7.645). AZN has higher annual earnings (EBITDA): 13.4B vs. BIIB (2.04B). AZN has more cash in the bank: 5.86B vs. BIIB (1.05B). BIIB has less debt than AZN: BIIB (7.34B) vs AZN (28.6B). AZN has higher revenues than BIIB: AZN (45.8B) vs BIIB (9.84B).
AZNBIIBAZN / BIIB
Capitalization209B31.3B668%
EBITDA13.4B2.04B658%
Gain YTD2.122-7.645-28%
P/E Ratio35.3026.95131%
Revenue45.8B9.84B466%
Total Cash5.86B1.05B558%
Total Debt28.6B7.34B390%
FUNDAMENTALS RATINGS
AZN vs BIIB: Fundamental Ratings
AZN
BIIB
OUTLOOK RATING
1..100
687
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
35100
SMR RATING
1..100
5267
PRICE GROWTH RATING
1..100
7565
P/E GROWTH RATING
1..100
6996
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZN's Valuation (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (84) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.

AZN's Profit vs Risk Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.

AZN's SMR Rating (52) in the Pharmaceuticals Major industry is in the same range as BIIB (67) in the Biotechnology industry. This means that AZN’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's Price Growth Rating (65) in the Biotechnology industry is in the same range as AZN (75) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to AZN’s over the last 12 months.

AZN's P/E Growth Rating (69) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that AZN’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNBIIB
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
53%
Bullish Trend 4 days ago
55%
Momentum
ODDS (%)
Bearish Trend 4 days ago
58%
Bearish Trend 4 days ago
66%
MACD
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
57%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
48%
Bearish Trend 4 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
45%
Bearish Trend 4 days ago
69%
Advances
ODDS (%)
Bullish Trend 12 days ago
55%
Bullish Trend 12 days ago
54%
Declines
ODDS (%)
Bearish Trend 4 days ago
47%
Bearish Trend 8 days ago
68%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
62%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
67%
View a ticker or compare two or three
Ad is loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

AZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZN has been loosely correlated with NVS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZN
1D Price
Change %
AZN100%
+1.87%
NVS - AZN
37%
Loosely correlated
-1.22%
MRK - AZN
35%
Loosely correlated
+0.61%
GSK - AZN
34%
Loosely correlated
+1.95%
BIIB - AZN
31%
Poorly correlated
+0.16%
OGN - AZN
29%
Poorly correlated
+2.86%
More

BIIB and

Correlation & Price change

A.I.dvisor tells us that BIIB and OGN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIIB and OGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+0.16%
OGN - BIIB
33%
Poorly correlated
+2.86%
PFE - BIIB
31%
Poorly correlated
+1.03%
NVS - BIIB
31%
Poorly correlated
-1.22%
AZN - BIIB
28%
Poorly correlated
+1.87%
JNJ - BIIB
24%
Poorly correlated
+1.93%
More